# Safety And Efficacy Of Rifabutin In HIV Patients

> **NCT00810446** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 72 (actual)

## Conditions studied

- Non-tuberculous Mycobacterial Diseases
- Tuberculosis
- Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections

## Interventions

- **DRUG:** rifabutin

## Key facts

- **NCT ID:** NCT00810446
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810446, "Safety And Efficacy Of Rifabutin In HIV Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00810446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*